. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008 Sep;7(9):796-804. PubMed.


Please login to recommend the paper.


Comments on this Paper

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:


  1. Soothing Neuroinflammation Quells Plaques in Mice